A clinical trial found that a new system can more accurately show correlation between improvement and worsening of prostate cancer, according to the company.
A Stony Brook-based company says it has developed a system that in a clinical trial correlated more closely to identifying prostate cancer’s development and defeat than PSA tests.
LineaRx said its system in a Phase II trial seeking recurrent prostate cancer demonstrates “the number of circulating tumor cells correlates more directly” with the status of the disease.
LineaRx, Inc., a subsidiary of Applied DNA Sciences, Inc, said its platform demonstrated “superior correlation over Prostate Specific Antigen or PSA” in an ongoing Phase II trial in recurrent prostate cancer.
A test used in a clinical trial more directly correlates with prostate cancer progress and worsening than PSA, according to a Stony Brook-based company.
“The concentration of invasive circulating tumor cells or iCTCs identified per milliliter of whole blood correlated more directly with disease status than PSA levels,” the company said.